Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a clinical-stage biotechnology company that is developing novel therapies aimed at enhancing the function of regulatory T cells (Tregs) in diseases with high unmet medical needs, such as neurodegenerative, chronic inflammatory, autoimmune, and metabolic conditions. The company's approach stands out from other therapies in the space as it targets the underlying immune dysregulation and chronic inflammation believed to drive disease progression, rather than just focusing on symptomatic relief or neuronal protection. Recent study data and biomarker findings have supported this approach, and the company's strong financial position allows for continued progress in its clinical pipeline.

Bears say

Coya Therapeutics is facing multiple challenges in the development of their Treg-enhancing therapies. Despite initial promise from biomarker modulation in an investigator-initiated study, there is no direct clinical efficacy update, and the company's COYA 302 drug is still in a randomized trial. Additionally, the company has highlighted various risk factors including regulatory, financial, and commercial risks that could further hinder their progress and success in bringing these therapies to market.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.